Guided Therapeutics (GTHP) Total Non-Current Liabilities (2013 - 2026)

Guided Therapeutics has disclosed Total Non-Current Liabilities across 14 years of filings, most recently posting $789000.0 for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 2154.29% year-over-year to $789000.0; the TTM figure through Jun 2026 stood at $789000.0 (up 2154.29% YoY), while the FY2025 annual figure was $694000.0, up 519.64% from the prior year.
• Total Non-Current Liabilities came in at $789000.0 for Q2 2026 at Guided Therapeutics, down from $818000.0 in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $1.7 million in Q1 2023 to a low of $35000.0 in Q2 2025.
• Average Total Non-Current Liabilities over 5 years is $705611.1, with a median of $693500.0 recorded in 2023.
• Year-over-year, Total Non-Current Liabilities tumbled 90.6% in 2024 and soared 2154.29% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $1.4 million in 2022, then sank by 51.74% to $666000.0 in 2023, then tumbled by 83.18% to $112000.0 in 2024, then jumped by 519.64% to $694000.0 in 2025, then climbed by 13.69% to $789000.0 in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $789000.0 in Q2 2026, $818000.0 in Q1 2026, and $694000.0 in Q4 2025.